Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines

Cortes-Funes, 2007, Role of anthracyclines in the era of targeted therapy, Cardiovasc. Toxicol., 7, 56, 10.1007/s12012-007-0015-3 Edwardson, 2015, Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines, Curr. Drug Metab., 16, 412, 10.2174/1389200216888150915112039 Rahman, 2007, Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation, Int. J. Nanomed., 2, 567 Marinello, 2018, Anthracyclines as topoisomerase II poisons: from early studies to new perspectives, Int. J. Mol. Sci., 19, 3480, 10.3390/ijms19113480 Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev., 56, 185, 10.1124/pr.56.2.6 Meredith, 2016, Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism, J. Pharm. Pharmacol., 68, 729, 10.1111/jphp.12539 Weiss, 1986, Anthracycline analogs: the past, present, and future, Cancer Chemother. Pharmacol., 18, 185, 10.1007/BF00273384 Arcamone, 1997, New developments in antitumor anthracyclines, Pharmacol. Ther., 76, 117, 10.1016/S0163-7258(97)00096-X Rivankar, 2014, An overview of doxorubicin formulations in cancer therapy, J. Cancer Res. Ther., 10, 853, 10.4103/0973-1482.139267 Plosker, 1993, Epirubicin, Drugs, 45, 788, 10.2165/00003495-199345050-00011 Ormrod, 1999, Epirubicin, Drugs Aging, 15, 389, 10.2165/00002512-199915050-00006 Hollingshead, 1991, Idarubicin, Drugs, 42, 690, 10.2165/00003495-199142040-00010 Tomankova, 2015, In vitro cytotoxicity analysis of doxorubicin-loaded/superparamagnetic iron oxide colloidal nanoassemblies on MCF7 and NIH3T3 cell lines, Int. J. Nanomed. Nanosurg., 10, 949, 10.2147/IJN.S72590 Kiyomiya, 2001, Mechanism of specific nuclear transport of adriamycin, Cancer Res., 61, 2467 Muindi, 1984, Hydroxyl radical production and DNA damage induced by anthracycline-iron complex, FEBS Lett., 172, 226, 10.1016/0014-5793(84)81130-8 Myers, 1977, Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response, Science, 197, 165, 10.1126/science.877547 Bose, 1995, Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals, Cell, 82, 405, 10.1016/0092-8674(95)90429-8 Jaffrézou, 1996, Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis, EMBO J., 15, 2417, 10.1002/j.1460-2075.1996.tb00599.x Denard, 2012, Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1, ELife, 1, 10.7554/eLife.00090 Simunek, 2009, Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol. Rep., 61, 154, 10.1016/S1734-1140(09)70018-0 Greene, 2014, The role of anthracyclines in the treatment of early breast cancer, J. Oncol, Pharm. Pract., 21, 201 2005, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Martin, 2005, Adjuvant docetaxel for node-positive breast cancer, N. Engl. J. Med., 352, 2302, 10.1056/NEJMoa043681 Owattanapanich, 2018, Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis, Clin. Lymphoma Myeloma Leuk., 18, 814, 10.1016/j.clml.2018.08.008 Sagi, 2016, Pharmacogenetics of anthracyclines, Pharmacogenomics, 17, 1075, 10.2217/pgs-2016-0036 Heywang, 1998, Orientation of Anthracyclines in lipid monolayers and planar asymmetrical bilayers: a surface-enhanced resonance raman scattering study, Biophys. J., 75, 2368, 10.1016/S0006-3495(98)77681-7 Gottesman, 2002, Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615, 10.1146/annurev.med.53.082901.103929 Endicott, 1989, The biochemistry of P-glycoprotein-mediated multidrug resistance, Annu. Rev. Biochem., 58, 137, 10.1146/annurev.bi.58.070189.001033 Roninson, 1992, From amplification to function: the case of the MDR1 gene, Mutat. Res., 276, 151, 10.1016/0165-1110(92)90005-T Raviv, 1990, Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells, J. Biol. Chem., 265, 3975, 10.1016/S0021-9258(19)39690-5 Nielsen, 1994, Relationship between resistance, P-glycoprotein content and steady-state accumulation in five series of Ehrlich ascites tumour cell lines selected for resistance to daunorubicin, Cell. Pharmacol., 1, 127 Nielsen, 1994, Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein: influence of verapamil, Biochem. Pharmacol., 47, 2125, 10.1016/0006-2952(94)90247-X Shieh, 2011, Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells, J. Control. Release, 152, 418, 10.1016/j.jconrel.2011.03.017 Cheah, 2017, Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: a randomized controlled and comparative spectral study in conscious rats, Nanotoxicology, 11, 210, 10.1080/17435390.2017.1285071 Ma, 2013, Anthracycline nano-delivery systems to overcome multiple drug resistance: a comprehensive review, Nano Today, 8, 313, 10.1016/j.nantod.2013.04.006 Vail, 2004, Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies, Semin. Oncol., 31, 16, 10.1053/j.seminoncol.2004.08.002 Seymour, 2009, Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer, Int. J. Oncol., 34, 1629, 10.3892/ijo_00000293 Yang, 2017, The light at the end of the tunnel-second generation HPMA conjugates for cancer treatment, Curr. Opin. Colloid Interface Sci., 31, 30, 10.1016/j.cocis.2017.07.003 Akasov, 2017, Novel doxorubicin derivatives: synthesis and cytotoxicity study in 2D and 3D in vitro models, Adv. Pharm. Bull., 7, 593, 10.15171/apb.2017.071 Weiss, 1992, The anthracyclines: will we ever find a better doxorubicin?, Semin. Oncol., 19, 670 Chhikara, 2012, Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate, J. Med. Chem., 55, 1500, 10.1021/jm201653u Yu, 2012, Synthesis and biological activities of a 3′-azido analogue of doxorubicin against drug-resistant cancer cells, Int. J. Mol. Sci., 13, 3671, 10.3390/ijms13033671 Piorecka, 2017, NMR analysis of antitumor drugs: doxorubicin, daunorubicin and their functionalized derivatives, Tetrahedron Lett., 58, 152, 10.1016/j.tetlet.2016.11.118 Kratz, 1998, Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy, J. Pharm. Sci., 87, 338, 10.1021/js970246a Chaikomon, 2018, Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance, Drug Des. Devel. Ther., 12, 2361, 10.2147/DDDT.S168588 2014, 137 Callaghan, 2014, Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?, Drug Metab. Dispos., 42, 623, 10.1124/dmd.113.056176 Ozols, 1987, Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients, J. Clin. Oncol., 5, 641, 10.1200/JCO.1987.5.4.641 List, 2001, Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study, Blood, 98, 3212, 10.1182/blood.V98.12.3212 Dalton, 1989, Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy, J. Clin. Oncol., 7, 415, 10.1200/JCO.1989.7.4.415 Tamaki, 2011, The controversial role of ABC transporters in clinical oncology, Essays Biochem., 50, 209, 10.1042/bse0500209 Cripe, 2010, Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999, Blood, 116, 4077, 10.1182/blood-2010-04-277269 Vazquez-Martin, 2009, The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy, Ann. Oncol., 20, 592, 10.1093/annonc/mdn758 Kim, 2011, Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation, Br. J. Pharmacol., 162, 1096, 10.1111/j.1476-5381.2010.01101.x Shafiei-Irannejad, 2018, Metformin enhances doxorubicin sensitivity via inhibition of doxorubicin efflux in P-gp-overexpressing MCF-7 cells, Chem. Biol. Drug Des., 91, 269, 10.1111/cbdd.13078 Cascone, 2018, Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy, Cell Metab., 27, 977, 10.1016/j.cmet.2018.02.024 Davies, 2017, Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer, PLoS One, 12, 10.1371/journal.pone.0187191 Genovese, 2018, Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents, Cancer Drug Resist., 1, 164 Van der Bliek, 1986, A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain, EMBO J., 5, 3201, 10.1002/j.1460-2075.1986.tb04630.x Landriscina, 2010, Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents, Cancer Res., 70, 6577, 10.1158/0008-5472.CAN-10-1256 Noordeen, 2012, Glucose-induced nuclear shuttling of ChREBP is mediated by sorcin and Ca(2+) ions in pancreatic beta-cells, Diabetes, 61, 574, 10.2337/db10-1329 Yamagishi, 2014, Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein, Biochem. Biophys. Res. Commun., 448, 430, 10.1016/j.bbrc.2014.04.125 Genovese, 2017, Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells, Cell Death Dis., 8, e2950, 10.1038/cddis.2017.342 Zhou, 2006, Sorcin, an important gene associated with multidrug-resistance in human leukemia cells, Leuk. Res., 30, 469, 10.1016/j.leukres.2005.08.024 Hu, 2013, Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins, Cancer chemother, Pharmacol., 72, 789 He, 2011, Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp, Oncol. Rep., 25, 237 Maddalena, 2011, Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca(2+) homeostasis, Cancer Res., 71, 7659, 10.1158/0008-5472.CAN-11-2172 Skovsgaard, 1994, Cellular resistance to cancer chemotherapy, Int. Rev. Cytol., 77, 10.1016/S0074-7696(08)62253-6 Versantvoort, 1992, Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression, Cancer Res., 52, 17 Chen, 2011, Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases, FEBS J., 278, 3226, 10.1111/j.1742-4658.2011.08235.x Grant, 1994, Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs, Cancer Res., 54, 357 Tiwari, 2011, Revisiting the ABCs of multidrug resistance in cancer chemotherapy, Curr. Pharm. Biotechnol., 12, 570, 10.2174/138920111795164048 Pratt, 2005, The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites, Mol. Cancer Ther., 4, 855, 10.1158/1535-7163.MCT-04-0291 Belinsky, 2002, Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6), Cancer Res., 62, 6172 Faneyte, 2004, Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement, Clin. Cancer Res., 10, 4457, 10.1158/1078-0432.CCR-03-0054 Chen, 1990, Characterization of adriamycinresistant human breast cancer cells which diplay overexpression of a novel resistancerelated membrane protein, J. Biol. Chem., 265, 10073, 10.1016/S0021-9258(19)38781-2 List, 1996, Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia, Blood, 87, 2464, 10.1182/blood.V87.6.2464.bloodjournal8762464 Meschini, 2002, Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells, Toxicol. In Vitro, 16, 389, 10.1016/S0887-2333(02)00035-8 Izquierdo, 1996, Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines, Br. J. Cancer Suppl., 74, 1961, 10.1038/bjc.1996.660 Doyle, 1995, Expresssion of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells, Br. J. Cancer Suppl., 71, 52, 10.1038/bjc.1995.11 Tsimberidou, 2002, Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia, Leuk. Res., 26, 143, 10.1016/S0145-2126(01)00106-0 Hugel, 2005, Membrane microparticles: two sides of the coin, Physiology, 20, 22, 10.1152/physiol.00029.2004 Bebawy, 2009, Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells, Leukemia, 23, 1643, 10.1038/leu.2009.76 Gong, 2013, Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance, Eur. J. Pharmacol., 721, 116, 10.1016/j.ejphar.2013.09.044 Zeman, 1998, Characterization of covalent adriamycin-DNA adducts, Proc. Natl. Acad. Sci. U. S. A., 95, 11561, 10.1073/pnas.95.20.11561 Spencer, 2008, DNA repair in response to anthracycline–DNA adducts: a role for both homologous recombination and nucleotide excision repair, Mutat. Res., 638, 110, 10.1016/j.mrfmmm.2007.09.005 Burgess, 2008, Topoisomerase levels determine chemotherapy response in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A., 105, 9053, 10.1073/pnas.0803513105 Deffie, 1992, Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topisomerase II, Biochem. Cell Biol., 70, 354, 10.1139/o92-055 Friche, 1991, Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells, Cancer Res., 51, 4213 Takano, 1992, DNA topoisomerase-targeting antitumor agents and drug resistance, Anticancer Drugs, 3, 323, 10.1097/00001813-199208000-00002 Pommier, 1994, Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors, Cancer Invest., 12, 530, 10.3109/07357909409021413 Chikamori, 2010, DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy, Curr. Cancer Drug Targets, 10, 758, 10.2174/156800910793605785 Jeon, 2018, Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells, Biochim. Biophys. Acta Gen. Subj., 1862, 1126, 10.1016/j.bbagen.2018.02.002 Oakman, 2009, The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients, Cancer Treat. Rev., 35, 662, 10.1016/j.ctrv.2009.08.006 Brase, 2010, ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction, Clin. Cancer Res., 16, 2391, 10.1158/1078-0432.CCR-09-2471 Kawachi, 2010, The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy, Pathol. Res. Pract., 206, 156, 10.1016/j.prp.2009.10.009 Di Leo, 2011, HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data, Lancet Oncol., 12, 1134, 10.1016/S1470-2045(11)70231-5 Du, 2011, The role of topoisomerase IIalpha in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures, Breast Cancer Res. Treat., 129, 839, 10.1007/s10549-011-1694-9 Nikolenyi, 2011, Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer, Oncology, 80, 269, 10.1159/000329038 O’Malley, 2011, Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial, Breast Cancer Res. Treat., 128, 401, 10.1007/s10549-011-1511-5 Trinh, 2013, Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs, Cancer Res., 73, 1000, 10.1158/0008-5472.CAN-12-3538 Jensen, 1993, Different modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance, Biochem. Pharmacol., 45, 2025, 10.1016/0006-2952(93)90013-M Iihoshi, 2017, Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells, Toxicol. Lett., 277, 109, 10.1016/j.toxlet.2017.06.006 Martins-Neves, 2018, Therapy-induced enrichment of cancer stem-like cells in solid human tumors: where do we stand?, Pharmacol. Res., 137, 193, 10.1016/j.phrs.2018.10.011 Visvader, 2008, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions, Nature Rev. Cancer, 8, 755, 10.1038/nrc2499 Richardson, 2004, CD133, a novel marker for human prostatic epithelial stem cells, J. Cell. Sci., 117, 3539, 10.1242/jcs.01222 Ricardo, 2011, Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype, J. Clin. Pathol., 64, 937, 10.1136/jcp.2011.090456 Liu, 2013, Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties, Chin. Med. J., 126, 3030 Dallas, 2009, Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition, Cancer Res., 69, 1951, 10.1158/0008-5472.CAN-08-2023 Xu, 2015, 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells, Int. J. Biol. Sci., 11, 284, 10.7150/ijbs.10248 Levina, 2008, Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties, PLoS One, 3, e3077, 10.1371/journal.pone.0003077 Hamilton, 2005, TLK-199 (Telik), IDrugs, 8, 662 Calcagno, 2010, Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics, J. Natl. Cancer Inst., 102, 1637, 10.1093/jnci/djq361 Jia, 2016, Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo, Oncotarget, 7, 771, 10.18632/oncotarget.5819 Cheng, 2018, Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066, Int. J. Oncol., 53, 339 Zheng, 2013, Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics, Cell Death Dis., 4, e740, 10.1038/cddis.2013.264 Li, 2017, Inhibition of KLF4 by statins reverses adriamycininduced metastasis and cancer stemness in osteosarcoma cells, Stem Cell Rep., 8, 1617, 10.1016/j.stemcr.2017.04.025 Santos, 2018, Exosome-mediated breast cancer chemoresistance via miR-155 transfer, Sci. Rep., 8, 829, 10.1038/s41598-018-19339-5 Lee, 2011, An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer, Br. J. Cancer Suppl., 104, 1730, 10.1038/bjc.2011.159 Annett, 2018, Targeting cancer stem cells in the clinic: current status and perspectives, Pharmacol. Ther., 187, 13, 10.1016/j.pharmthera.2018.02.001 Staubert, 2015, Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine, J. Biol. Chem., 290, 8348, 10.1074/jbc.M114.618769 Bean, 2014, Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma, J. Pediatr. Surg., 49, 981, 10.1016/j.jpedsurg.2014.01.037 Ganapathy-Kanniappan, 2010, 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy, Curr. Pharm. Biotech., 11, 510, 10.2174/138920110791591427 Nakano, 2011, Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells, PLoS One, 6, 10.1371/journal.pone.0027222 Jones, 2005, AMP-activated protein kinase induces a p53-dependent metabolic checkpoint, Mol. Cell, 18, 283, 10.1016/j.molcel.2005.03.027 Ma, 2015, Targeting cellular metabolism chemosensitizes the doxorubicin-resistant human breast adenocarcinoma cells, Biomed Res. Int., 10.1155/2015/453986 Coleman, 2008, 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer, Free Radic. Biol. Med., 44, 322, 10.1016/j.freeradbiomed.2007.08.032 Hua, 2014, Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A, Oncol. Rep., 31, 2727, 10.3892/or.2014.3156 Zhang, 2017, Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway, Mol. Med. Rep., 15, 1869, 10.3892/mmr.2017.6189 Di Cosimo, 2003, Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors, Drugs Today, 39, 157, 10.1358/dot.2003.39.3.799451 Ferretti, 1993, Pentose phosphate pathway alterations in multi-drug resistant leukemic T-cells: 31P NMR and enzymatic studies, Anticancer Res., 13, 867 Todor, 2015, Metabolic changes during development of Walker-256 carcinosarcoma resistance to doxorubicin, Exp. Oncol., 37, 19, 10.31768/2312-8852.2015.37(1):19-22 Eisele, 2007, Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia, Acta Haematol., 117, 8, 10.1159/000096854 Brown, 2017, Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer, Cancer Discov., 7, 391, 10.1158/2159-8290.CD-16-0611 Wu, 2018, Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells, Haematologica, 103, 1472, 10.3324/haematol.2018.188185 Aquilano, 2014, Glutathione: new roles in redox signaling for an old antioxidant, Front. Pharmacol., 5, 196, 10.3389/fphar.2014.00196 Polimeni, 2011, Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity, Biochem. J., 439, 141, 10.1042/BJ20102016 Ginsberg, 2009, Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity, J. Toxicol. Environ. Health B Crit. Rev., 12, 389, 10.1080/10937400903158375 Lo, 2007, Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance, Curr. Opin. Pharmacol., 7, 367, 10.1016/j.coph.2007.06.009 Morrow, 1998, Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells, J. Biol. Chem., 273, 20114, 10.1074/jbc.273.32.20114 Smitherman, 2004, Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity, J. Pharmacol. Exp. Ther., 308, 260, 10.1124/jpet.103.057729 Franco, 2007, The central role of glutathione in the pathophysiology of human diseases, Arch. Physiol. Biochem., 113, 234, 10.1080/13813450701661198 Drozd, 2016, Up-regulation of glutathione-related genes, enzyme activities and transport proteins in human cervical cancer cells treated with doxorubicin, Biomed. Pharmacother., 83, 397, 10.1016/j.biopha.2016.06.051 Batist, 1986, Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells, J. Biol. Chem., 261, 15544, 10.1016/S0021-9258(18)66748-1 Traverso, 2013, Role of glutathione in cancer progression and chemoresistance, Oxid. Med. Cell. Longev., 10.1155/2013/972913 Wu, 2010, Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1, Chem. Biol. Drug Des., 75, 475, 10.1111/j.1747-0285.2010.00955.x Vergote, 2009, Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer, Eur. J. Cancer, 45, 2324, 10.1016/j.ejca.2009.05.016 Raza, 2009, Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome, Blood, 113, 6533, 10.1182/blood-2009-01-176032 Raza, 2012, A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome, Cancer, 118, 2138, 10.1002/cncr.26469 Liu, 2008, A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction, Mol. Cancer Ther., 7, 263, 10.1158/1535-7163.MCT-07-0445 Rysman, 2010, De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation, Cancer Res., 70, 8117, 10.1158/0008-5472.CAN-09-3871 Meena, 2013, Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved, PLoS One, 8, 10.1371/journal.pone.0061524 Liu, 2012, Enhanced antitumor activity of epirubicin combined with cerulenin in osteosarcoma, Mol. Med. Rep., 5, 326 Regev, 2005, Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism, Biochem. Pharmacol., 70, 161, 10.1016/j.bcp.2005.03.032 Liu, 2013, Fatty acid synthase causes drug resistance by inhibiting TNF-alpha and ceramide production, J. Lipid Res., 54, 776, 10.1194/jlr.M033811 Brenner, 2015, First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, J. Clin. Oncol., 10.1200/jco.2015.33.15_suppl.tps2615 Ventura, 2015, Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression, EBioMedicine, 2, 808, 10.1016/j.ebiom.2015.06.020 Zaytseva, 2018, Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer, Oncotarget, 9, 24787, 10.18632/oncotarget.25361 Lo, 2015, Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer, J. Cell. Mol. Med., 19, 744, 10.1111/jcmm.12388 Tapiero, 1986, Changes in biophysical parameters and in phospholipid composition associated with resistance to doxorubicin, Anticancer Res., 6, 649 Dubois, 1992, Variation of choline-substituted lipid metabolism in doxorubicin-resistant leukemia cells, Biomed. Pharmacother., 46, 485, 10.1016/0753-3322(92)90006-S Todor, 2012, The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells, Exp. Oncol., 34, 97 Cai, 2004, Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox, Biochem. Biophys. Res. Commun., 320, 868, 10.1016/j.bbrc.2004.06.030 Samuels, 2014, A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia, Blood Cancer J., 4, e232, 10.1038/bcj.2014.52 Fanciulli, 1993, Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells, Oncol. Res., 5, 357 Guo, 2016, Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells, BMC Cancer, 16, 762, 10.1186/s12885-016-2790-3 Lin, 2010, Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer, Mol. Cancer Res., 8, 1217, 10.1158/1541-7786.MCR-10-0162 Pan, 2015, Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin, Genet. Mol. Res., 14, 5621, 10.4238/2015.May.25.14 Glick, 2010, Autophagy: cellular and molecular mechanisms, J. Pathol., 221, 3, 10.1002/path.2697 Sui, 2013, Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment, Cell Death Dis., 4, e838, 10.1038/cddis.2013.350 Ren, 2016, Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer, Biochim. Biophys. Acta, 1866, 266 Li, 2017, Autophagy and multidrug resistance in cancer, Chin. J. Cancer, 36, 10.1186/s40880-017-0219-2 Tan, 2015, Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy, Cancer Sci., 106, 1023, 10.1111/cas.12712 Yousefi, 2006, Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis, Nature Cell Biol., 8, 1124, 10.1038/ncb1482 Chittaranjan, 2014, Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer, Clin. Cancer Res., 20, 3159, 10.1158/1078-0432.CCR-13-2060 Sun, 2018, Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12, Cancer Sci., 109, 3129, 10.1111/cas.13743 Sun, 2011, Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development, Autophagy, 7, 1035, 10.4161/auto.7.9.16521 Zhang, 2016, Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells, Apoptosis, 21, 473, 10.1007/s10495-016-1214-9 Ge, 2014, Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer, PLoS One, 9, 10.1371/journal.pone.0110293 Blum, 2017, Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology), J. Clin. Oncol., 35, 2647, 10.1200/JCO.2016.71.4147 Pisano, 2013, Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer, J. Drug Deliv., 2013, 10.1155/2013/898146 Massacesi, 2000, Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer, J. Exp. Clin. Cancer Res., 19, 13 Azim, 2010, High dose intensity doxorubicin in aggressive non-Hodgkin’s lymphoma: a literature-based meta-analysis, Ann. Oncol., 21, 1064, 10.1093/annonc/mdp425 Petrioli, 2016, Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: a systematic review and meta-analysis, Crit. Rev. Oncol. Hematol., 102, 82, 10.1016/j.critrevonc.2016.04.001 Lopez-Gonzalez, 2013, The role of anthracyclines in small cell lung cancer, Ann. Transl. Med., 1, 5 Petrioli, 2002, Weekly epirubicin in patients with hormone-resistant prostate cancer, Br. J. Cancer, 87, 720, 10.1038/sj.bjc.6600525 In, 2017, Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations, Ther. Adv. Med. Oncol., 9, 533, 10.1177/1758834017712963 Nielsen, 2000, Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC Soft Tissue and Bone Sarcoma Group, Sarcoma, 4, 31, 10.1155/S1357714X00000062